Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on invested capital (ROIC) high or low?
The return on invested capital (ROIC) of 6.72% is 370% above its 5-year average of -2.49%, near the high end of its 5-year range (-8.14%–6.72%).
As of the fiscal period ended Tuesday, June 30, 2026. 90.08% above its 12-month average of 3.54%.
Trailing-twelve-month return on invested capital at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): 6.72%.
RETURN ON INVESTED CAPITAL (ROIC)
6.72%
RETURN ON INVESTED CAPITAL (ROIC) AVG TTM
3.54%
RETURN ON INVESTED CAPITAL (ROIC) AVG 3Y
-0.80%
RETURN ON INVESTED CAPITAL (ROIC) AVG 5Y
-2.49%
RETURN ON INVESTED CAPITAL (ROIC) AVG 10Y
-9.15%
RETURN ON INVESTED CAPITAL (ROIC) AVG 15Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 20Y
N/A
CURRENT VS TTM AVG
+90.08%
CURRENT VS 3Y AVG
+937.88%
CURRENT VS 5Y AVG
+369.62%
CURRENT VS 10Y AVG
+173.45%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-35.66%
median of 837 covered companies
CURRENT VS SECTOR MEDIAN
+118.85%
vs the sector median at left
Veracyte, Inc.
Market Cap
$3.56B
Return on Invested Capital (ROIC)
6.72%
TTM Avg
3.54%
3Y Avg
-0.80%
5Y Avg
-2.49%
Market Cap
$3.57B
Return on Invested Capital (ROIC)
-12.91%
TTM Avg
-40.91%
3Y Avg
-35.75%
5Y Avg
-31.17%
Market Cap
$3.54B
Return on Invested Capital (ROIC)
-35.27%
TTM Avg
-38.13%
3Y Avg
-29.19%
5Y Avg
-24.81%
Market Cap
$3.52B
Return on Invested Capital (ROIC)
-1.07%
TTM Avg
-9.16%
3Y Avg
-22.10%
5Y Avg
-20.63%
Market Cap
$3.64B
Return on Invested Capital (ROIC)
-69.75%
TTM Avg
-63.60%
3Y Avg
-55.78%
5Y Avg
-83.39%
Market Cap
$3.48B
Return on Invested Capital (ROIC)
-17.68%
TTM Avg
-22.74%
3Y Avg
-21.16%
5Y Avg
-18.86%
Market Cap
$3.47B
Return on Invested Capital (ROIC)
-28.15%
TTM Avg
-46.92%
3Y Avg
-38.64%
5Y Avg
-44.96%
Market Cap
$3.44B
Return on Invested Capital (ROIC)
-79.40%
TTM Avg
-65.84%
3Y Avg
-73.62%
5Y Avg
-96.54%
Market Cap
$3.38B
Return on Invested Capital (ROIC)
6.25%
TTM Avg
16.80%
3Y Avg
-7.33%
5Y Avg
-16.60%
| NAME | MARKET CAP | RETURN ON INVESTED CAPITAL (ROIC) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Veracyte, Inc. (VCYT) | $3.56B | 6.72% | 3.54% | -0.80% | -2.49% |
| Tango Therapeutics, Inc. (TNGX)vs › | $3.57B | -12.91% | -40.91% | -35.75% | -31.17% |
| Xenon Pharmaceuticals Inc. (XENE)vs › | $3.54B | -35.27% | -38.13% | -29.19% | -24.81% |
| iRhythm Technologies, Inc. (IRTC)vs › | $3.52B | -1.07% | -9.16% | -22.10% | -20.63% |
| Regencell Bioscience Holdings Limited (RGC)vs › | $3.64B | -69.75% | -63.60% | -55.78% | -83.39% |
| IDEAYA Biosciences, Inc. (IDYA)vs › | $3.48B | -17.68% | -22.74% | -21.16% | -18.86% |
| Celcuity Inc. (CELC)vs › | $3.47B | -28.15% | -46.92% | -38.64% | -44.96% |
| Pulse Biosciences, Inc. (PLSE)vs › | $3.44B | -79.40% | -65.84% | -73.62% | -96.54% |
| Acadia Pharmaceuticals Inc. (ACAD)vs › | $3.38B | 6.25% | 16.80% | -7.33% | -16.60% |
| Parabilis Medicines, Inc. (PBLS)vs › | $3.36B | -409.85% | -257.76% | -257.76% | -257.76% |
ROIC
6.7%
ROE
8.3%
ROIC = NOPAT / Invested Capital, where NOPAT = Operating Income × (1 − effective tax rate) and Invested Capital = Total Assets − (Current Liabilities − Short-Term Debt)
Return on invested capital measures the after-tax operating return a company earns on the capital invested in the business. TGMCharts computes it from reported statements: trailing-twelve-month operating income after tax, over invested capital at the latest balance sheet — total assets less the non-interest-bearing current liabilities (payables, accruals, deferred revenue) that fund them; short-term debt stays in the capital base. The tax rate is the period's own effective rate (income tax ÷ pretax income), capped at 45%; when pretax income is zero or negative, or the tax line is a net benefit, no tax is deducted — the operating figure is shown untaxed rather than adjusted by an assumed rate. Not shown for banks, insurers or funds.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON INVESTED CAPITAL (ROIC) |
|---|---|
| 2026-06-30 | 6.72% |
| 2026-03-31 | 4.74% |
| 2025-12-31 | 3.36% |
| 2025-09-30 | 1.87% |
| 2025-06-30 | 0.99% |
| 2025-03-31 | 1.80% |
| 2024-12-31 | 1.24% |
| 2024-09-30 | -1.95% |
| 2024-06-30 | -5.79% |
| 2024-03-31 | -7.00% |
| 2023-12-31 | -8.14% |
| 2023-09-30 | -5.22% |
| 2023-06-30 | -3.05% |
| 2023-03-31 | -3.30% |
| 2022-12-31 | -3.76% |
| 2022-09-30 | -4.49% |
| 2022-06-30 | -5.06% |
| 2022-03-31 | -4.65% |
| 2021-12-31 | -7.28% |
| 2021-09-30 | -6.83% |
| 2021-06-30 | -6.56% |
| 2021-03-31 | -6.91% |
| 2020-12-31 | -8.04% |
| 2020-09-30 | -8.07% |
| 2020-06-30 | -13.63% |
| 2020-03-31 | -10.19% |
| 2019-12-31 | -5.87% |
| 2019-09-30 | -4.10% |
| 2019-06-30 | -5.28% |
| 2019-03-31 | -14.05% |
| 2018-12-31 | -20.41% |
| 2018-09-30 | -23.21% |
| 2018-06-30 | -49.54% |
| 2018-03-31 | -47.14% |
| 2017-12-31 | -39.82% |
| 2017-09-30 | -33.36% |
| 2017-06-30 | -29.25% |
| 2017-03-31 | -31.94% |
| 2016-12-31 | -32.18% |
| 2016-09-30 | -55.71% |
| 2016-06-30 | -58.87% |
| 2016-03-31 | -49.27% |
| 2015-12-31 | -55.26% |
| 2015-09-30 | -51.32% |
| 2015-06-30 | -45.96% |
| 2015-03-31 | -73.29% |
| 2014-12-31 | -60.82% |
| 2014-09-30 | -48.36% |
| 2014-06-30 | -48.46% |
| 2014-03-31 | -41.51% |
| 2013-12-31 | -36.07% |
| 2013-09-30 | -203.85% |
| 2013-06-30 | -123.03% |
